UNI MEDICAL (02666) plans to invest 15.03 million yuan to establish a joint venture company, which will build a collaborative platform integrating policy coordination, technology transfer, and clinical validation.

UNI MEDICAL (02666) announced that on November 18, 2025 (after trading hours), the company, China General Technology Group (an indirect wholly-owned subsidiary of ), and Harmony Technology signed an agreement to establish a joint venture company. According to the agreement, the registered capital of the joint venture company is RMB 30 million, to be contributed in cash by the relevant parties, with the company contributing RMB 15.03 million, contributing RMB 4.47 million, and Harmony Technology contributing RMB 10.5 million. After the establishment of the joint venture company, the company, , and Harmony Technology will hold 50.1%, 14.9%, and 35% respectively, making the joint venture company a subsidiary of the company. The establishment of the joint venture company aims to fully utilize the related franchise policies of the Hainan Bo'ao Lecheng International Medical Tourism Pioneer Zone, including but not limited to the fast approval channel for urgently needed imported medical devices under the "Nine National Policies" framework, the application pilot of real-world data, and the facilitation of overseas physician practice, in order to achieve the fast registration, clinical application, and commercialization of international Innovative Medical Management devices in China. Through collaboration with the management authority of the pioneer zone, medical institutions, and industry partners, the joint venture company will build a synergistic platform integrating policy alignment, technology transfer, and clinical validation, further accelerating the access of global cutting-edge medical technology in China, enhancing the efficiency of clinical transformation of innovative outcomes, and increasing commercial value. The company believes that this cooperation aligns with the national strategy of promoting medical innovation and high-level opening up to the outside world, enriching the company's medical device business pipeline, and creating long-term value for shareholders.